Obesity in adults: a review
DOI:
https://doi.org/10.18203/2320-6012.ijrms20251029Keywords:
Obesity, Body mass index, Waist circumference, Type 2 diabetesAbstract
Obesity is a chronic complex disease that is caused by excessive fat deposits in the human body, and it is considered as one of the major causes of health impairment. It increases the risk of type 2 diabetes and heart diseases in addition to affecting bones and reproduction system that can increase the risk of certain types of cancer. Furthermore, it has a major impact on the quality of living, such as sleeping disorder or physical movement. Its early diagnostic procedure involves a regular monitoring of the human’s body mass index (BMI): weight (kg)/height2 (m2). The body mass index is an initial surrogate marker to confirm fatness and waist circumference that helps to diagnose obesity. It is an emerging and growing public health issue in the Western world as well as in the Middle East countries. More specifically, obesity in Qatar is the focus in this article which is among the top-ranked obese countries with a high obesity rate among its population and only a limited number of studies focused on the systematic identification of potential risk factors using multimodal datasets. This article aims to focus on the main causes of obesity, its diagnosis, management approach and pharmacological and non-pharmacological treatments.
Metrics
References
NICE Clinical guideline CG189. Obesity: identification, assessment and management. 2023. Available at: https://www.ncbi.nlm.nih.gov/books/ NBK588750/. Accessed on 22 December 2024.
World Health Organization. Obesity and overweight. 2024. Available at: https://www.who.int/news-room/ fact-sheets/detail/obesity-and-overweight. Accessed on 22 December 2024.
World Obesity Federation. The Economic Impact of Overweight & Obesity In 8 Countries. Summary report. 2021. Available at: https://data.worldobesity. org/publications/. Accessed on 22 December 2024.
Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-23. DOI: https://doi.org/10.1111/obr.12551
Mandeya J, Kridli SAO. Childhood overweight and obesity in Qatar: A literature review. Avicenna. 2014;2014:2. DOI: https://doi.org/10.5339/avi.2014.2
Chanpong GF. Qatar 2006 world health survey overview. World Health Organization Eastern Mediterranean Regional Health System Observatory's Qatar Primary Health Care Conference. Doha, Qatar. 2008.
Haj Bakri A, Al-Thani A. Chronic Disease Risk Factor Surveillance: Qatar STEPS Report 2012. The Supreme Council of Health. Doha, Qatar. 2013. Available at: https://cdn.who.int/media/docs/default-source/ncds/ncd-surveillance/data-reporting/qatar/ steps/qatar-factsheet-2012. Accessed on 22 December 2024.
Verhaegen AA, Van Gaal LF. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al, editors. Endotext. South Dartmouth (MA): MDText.com, Inc. 2000.
Taghavi SA, van Wely M, Jahanfar S, Bazarganipour F. Pharmacological and non‐pharmacological strategies for obese women with subfertility. Cochrane Database Syst Rev. 2017;2017(4):CD012650. DOI: https://doi.org/10.1002/14651858.CD012650
Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry. 1999;60(21):31-6.
Fujioka K. Management of Obesity as a Chronic Disease: Nonpharmacologic, Pharmacologic, and Surgical Options. Obesity Res. 2002;10:116S-23S. DOI: https://doi.org/10.1038/oby.2002.204
Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882. DOI: https://doi.org/10.1016/j.eclinm.2023.101882
Schmitz SH, Aronne LJ. The Effective Use of Anti-obesity Medications. Gastroenterol Clin North Am. 2023;52(4):661-80. DOI: https://doi.org/10.1016/j.gtc.2023.08.003
Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000;20(3):270-9. DOI: https://doi.org/10.1592/phco.20.4.270.34882
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. DOI: https://doi.org/10.1016/j.molmet.2020.101102
Downloads
Published
How to Cite
Issue
Section
